As knockdown of TAZ was found to reduce the TRAIL resistance in the established TRAIL-resistant glioma models, we demonstrated that TAZ can be a potential target during the TRAIL-based chemotherapy of glioma. This evidence concerns the gene TAFAZZIN and glioma.